

REMARKS/ARGUMENTS

Applicants would like to thank Examiner Desai for the indication of allowable subject matter in the present application.

Claims 1-18 are active in the present application, claims 19-20 having been cancelled by the present amendment. The Specification has been amended to correct the representation of Formula I to show the group X connected generically to the aryl ring, not to a specific position. This amendment is supported by the method of its preparation and Formula for the precursors thereof provided in the specification and the claims as originally presented.

Claims 1 and 12 have been amended to delete the non-elected subject matter of Formula II, and to correct the representation of Figure I to show the group X connected generically to the aryl ring. Again this amendment is supported by the specification which provides similar arrangement for Formula II and the method of preparation and precursors for forming the compounds of Formula I.

Claims 12 and 13 have been further amended to indicate that the group R is an aryl or silyl bearing group, with the remaining embodiments of R deleted. This amendment is supported by the claims as originally filed.

No new matter has been added by these amendments.

Claims 12-20 stand rejected under 35 U.S.C. 102(b) over Loos et al or Wall et al. Neither of these references disclose or suggest a camptothecin compound having a substituent at the 7-position (substituent R of the present claims) that is either an aryl containing or silicon containing substituent. In fact, the only compounds disclosed by either of these references are a single compound having the 7-Methyl substituent (Loos et al) and a generic structure where the 7-position must be either H or C1-8 alkyl (Wall et al). Accordingly, there is nothing within either reference that would anticipate (or render obvious) a compound

wherein the 7-position is substituted by an aryl containing group, or a group containing a silicon atom.

Claims 12-20 stand further rejected as obvious under 35 U.S.C. 103 over Wall et al or Fang et al. Again, neither of these references disclose or suggest a compound having a substituent at the 7-position that contains an aryl group or a silicon. Wall et al has been discussed above, and only shows a 7-position group that is H or C1-8 alkyl. Fang et al disclose camptothecin compounds which can have a variety of substituents at the 7-position. However, of the embodiments disclosed therein, none are aryl containing groups and none contain silicon. Accordingly, Fang et al cannot suggest the present claims 12-20 as amended.

Since none of the references cited disclose or suggest the compounds as now claimed, the rejections of claims 12-20 should be withdrawn.

The objection to claim 1 has been obviated by the present amendment.

Applicants submit that the application is now in condition for allowance and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



J. Derek Mason, Ph.D.

Attorney of Record

Registration No. 35,270

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)